Iovance Biotherapeutics, Inc.

This study tests a treatment made from a patient's own immune cells (called TILs) that are taken from their tumor, multiplied in a lab, and given back to fight metastatic non-small-cell lung cancer. About 170 adults with stage IV lung cancer that has spread will receive this one-…

This study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…

This early-stage trial tests a new drug (IOV-3001) combined with an immune cell therapy (lifileucel) in adults with advanced melanoma that has stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can help control the disease. About…

This study tests whether a personalized immune cell therapy called lifileucel can shrink tumors in people with advanced endometrial cancer that has not responded to prior treatments. About 60 participants will receive their own tumor-fighting immune cells grown in a lab. The main…

This program offers AMTAGVI, a cell therapy, to people with advanced melanoma that cannot be removed by surgery or has spread. It is for patients who already had a batch made for commercial use, but that batch did not meet all quality standards—though it was still considered safe…